Merck
CN

Plasma pteridine concentrations in patients with chronic renal failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2002-05-29)
Keitaro Yokoyama, Masamich Tajima, Hiraku Yoshida, Masaaki Nakayama, Goro Tokutome, Hiroshi Sakagami, Tatsuo Hosoya
摘要

Pteridine metabolism is impaired in the uraemic state. This may affect cardiovascular function and contribute to malnutrition. We wished to clarify further the impact of impaired pteridine metabolism. Using the HPLC method, the plasma concentrations of endogenous pteridines were determined in 64 patients with chronic renal failure (33 on intermittent haemodialysis (HD) treatment vs 31 not yet on renal replacement therapy), and in 18 healthy controls. The patients were classified into three groups on the basis of creatinine clearance (Ccr): group (a), Ccr >60 ml/min; group (b), Ccr=10-60 ml/min; group (c), all patients receiving HD. Total neopterin (NP) and biopterin (BP) levels and the NP/BP ratio (a biomarker for macrophage activity) were significantly higher, whereas tetrahydrobiopterin (BH(4))/dihydrobiopterin (BH(2)) ratio (a biomarker for nitric oxide synthase and phenylalanine hydroxylase activities) was significantly lower in group (c) (118.9+/-11.7 ng/ml, 18.8+/-1.2 ng/ml, 6.79+/-0.53, and 0.26+/-0.06) than in healthy subjects (5.17+/-0.29 ng/ml, 2.83+/-0.19 ng/ml, 1.92+/-0.13, and 1.15+/-0.11; P<0.01). These significant differences were also observed between control and group (b) (12.4+/-2.20 ng/ml, 4.48+/-0.36 ng/ml, 2.81+/-0.48, and 0.74+/-0.08; P<0.01). In groups (a) and (b), significant negative correlations were found between Ccr and the total NP level (r=-0.663, P<0.01), the total BP level (r=-0.492, P<0.01), the BH(2) level (r=-0.677, P<0.01), and the NP/BP ratio (r=-0.493, P<0.01). Conversely, significant positive correlations were found between Ccr and the BH(4)/BH(2) ratio (r=0.602, P<0.01). The reduction of quinoid-type BH(2) to BH(4) is modified in patients with advanced chronic renal failure, before and after the initiation of regular HD treatment. These metabolic alterations may play a role in the impaired macrophage, endothelial constitutive nitric oxide synthase, or phenylalanine hydroxylase (PH) activities observed in such patients.

材料
货号
品牌
产品描述

Sigma-Aldrich
纯乙醇, 200 proof, for molecular biology
Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.9%
Sigma-Aldrich
丙酮, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
纯乙醇, 200 proof, HPLC/spectrophotometric grade
Sigma-Aldrich
酒精, BioUltra, for molecular biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
乙醇,变性, reagent grade
Sigma-Aldrich
酒精试剂, reagent grade
Supelco
酒精, standard for GC
Sigma-Aldrich
纯乙醇, 190 proof, for molecular biology
Sigma-Aldrich
丙酮, Laboratory Reagent, ≥99.5%
Supelco
无水乙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
丙酮, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Supelco
丙酮, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
丙酮, analytical standard
Sigma-Aldrich
肌苷, ≥99% (HPLC)
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.8%
Sigma-Aldrich
酒精试剂, suitable for HPLC
Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
三甲胺N-氧化物, 95%
Sigma-Aldrich
酒精试剂, anhydrous, ≤0.003% water
Sigma-Aldrich
三甲胺 溶液, 43.0-49.0% in H2O (T)
Sigma-Aldrich
尸胺, 95%
Sigma-Aldrich
酒精试剂, anhydrous, ≤0.005% water
Sigma-Aldrich
三甲胺 溶液, 31-35 wt. % in ethanol, 4.2 M, contains toluene as stabilizer